ERBB2 and invasive ductal breast carcinoma: Pathologically, all cases were invasive ductal carcinoma (IDC) and estrogen receptor (ER) positive, 97.8% were progesterone receptor (PR) positive and 24.5% had human epidermal growth factor receptor 2 (HER2) over-expression.